• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Former Merck Unit Works on First Vaccine for Hepatitis C

Article

Merck & Co. (MRK)

Okairos AG, a biotechnology business that sold to venture capital funds in 2007, is seeking to produce the first preventive vaccine for hepatitis C, challenging makers of treatments for the disease.

Okairos has begun a mid-stage study, funded by the U.S. National Institutes of Health, of a gene-based vaccine designed to stimulate the body’s immune system to prevent hepatitis C from taking hold, Chief Operating Officer Tom Woiwode said in a phone interview from the company’s Basel, Switzerland, headquarters.

Read the full story: http://hcp.lv/xJg8Qg

Source: Bloomberg

Related Videos
Dr Susan Vadaparampil
Luke Messac at ISC 2026
2 experts are featured in this series.
Ava Liberman at ISC 2026
Alison Holman at ISC 2026
Dr Ameet Patel
Linda Stein Gold, MD
Eric Levin, Scripta
Dr. Emily Fisher at ISC 2026
© 2026 MJH Life Sciences
AJMC®
All rights reserved.